Promoting hair regrowth, Pfizer initiates new Phase III clinical trial for alopecia areata drug in China.

Source:Drug Clinical Trial Registration and Information Disclosure Platform Official

This is a randomized, double-blind, placebo-The multi-center Phase III clinical trial for the drug candidate aimsSever AA In pediatric subjects, evaluate the efficacy of liticitinib compared to placebo inScalp hair lossThe efficacy of.

The study plans to enroll 35 subjects domestically and 225 subjects internationally, who will be randomly assigned to receiveLitretuxinib 30mgLitrit50mg, Placebo 50mg, Placebo 30. On August 28, 2025, the first international patient enrollment was completed

Source:  The following content may be helpful for translation:Drug Clinical Trial Registration and Information Disclosure Platform Official

ResearchThe primary endpoint isAt week 24 based on the Alopecia Severity Instrument (SALT) Responses with an absolute score ≤ 20.SecondaryChange from baseline in SALT score at (CFB)，All visits(except for visits included in the primary endpoint)Response based on a SALT absolute score ≤ 10, among

Litritinib is aDual-channel inhibitor of the JAK3/TEC kinase, taken orally once daily. In June 2023, this product was first launched in the United States and entered the Chinese market in October of the same year, indicated for the treatment of severe alopecia areata in adolescents and adults aged 12 years and older

Cover Source:  The following content may be helpful for translation:Corporate

Disclaimer:                The following content may be helpful for translation:This article is for informational purposes only and does not represent the stance or views of Insight, nor does it recommend or introduce treatment options. If needed, please consult and contact a正规医疗机构

Editor: Crescent

PR Draft Coordination: WeChat insight